4DMT to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF, Extend Cash Runway

 

• Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis
• After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectively
• Primary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027
• Cash runway extended under updated operating plan; unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024 expected to fund operations into 2028

https://www.globenewswire.com/news-release/2025/01/10/3007636/0/en/4DMT-Focuses-Pipeline-to-Prioritize-4D-150-in-Wet-AMD-DME-and-4D-710-in-CF-and-Extends-Cash-Runway.html